Ann Lab Med.  2017 Mar;37(2):177-179. 10.3343/alm.2017.37.2.177.

Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia

• Yu N
• Shin S
• Choi JR
• Kim Y
• Lee KA

• KMID: 2373641
• DOI: http://doi.org/10.3343/alm.2017.37.2.177

Abstract

No abstract available.

MeSH Terms

Aged
Cytidine Deaminase/*genetics/metabolism
Dasatinib/therapeutic use
Disease Progression
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl/genetics/metabolism
Humans
Imatinib Mesylate/*therapeutic use
In Situ Hybridization, Fluorescence
Karyotype
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Male
Microfilament Proteins/*genetics/metabolism
Oncogene Proteins/*genetics/metabolism
Protein Kinase Inhibitors/*therapeutic use
Cytidine Deaminase
Dasatinib
Fusion Proteins, bcr-abl
Imatinib Mesylate
Microfilament Proteins
Oncogene Proteins
Protein Kinase Inhibitors

Figure

• 

  Fig. 1 Genetic analysis of CML-AP BM samples. (A) Translocation site in G-banded karyotyping of the 46,XY,t(5;12)(p13;p13) (arrows). (B) Interphase FISH confirming three signals of the AID probe (red), resulting from AID rearrangement at the 12p13 locus. (4,6-diamidino-2-phenylindole stain, ×1,000). (C) Chromosomal microarray revealing copy number loss in the chromosome 12q24.31 region (arrow). Blue dots with a log2 transformed value of -1 represent a 1:2 copy number ratio to the reference genomic DNA, indicating a heterozygous deletion. The expansion view of the 12q24 region reveals a 1.9-Mb heterozygous interstitial deletion in chromosome 12 (121,949,449-123,968,599; hg19) that includes the BCL7A gene.Abbreviations: AP, accelerated phase; BM, bone marrow; AID, activation-induced cytidine deaminase; BCL7A, B-cell CLL/lymphoma 7A.

Reference

1. Strout MP, Schatz DG. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way. Cancer Cell. 2009; 16:174–176. PMID: 19732715.

2. Neviani P. Genetic events other than BCR-ABL1. Curr Hematol Malig Rep. 2014; 9:24–32. PMID: 24407376.

3. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009; 16:232–245. PMID: 19732723.

4. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007; 204:1157–1166. PMID: 17485517.

5. Ugarte GD, Vargas MF, Medina MA, León P, Necuñir D, Elorza AA, et al. Wnt signaling induces transcription, spatial proximity, and translocation of fusion gene partners in human hematopoietic cells. Blood. 2015; 126:1785–1789. PMID: 26333776.

6. Kato L, Begum NA, Burroughs AM, Doi T, Kawai J, Daub CO, et al. Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes. Proc Natl Acad Sci U S A. 2012; 109:2479–2484. PMID: 22308462.

7. Uehara T, Kage-Nakadai E, Yoshina S, Imae R, Mitani S. The tumor suppressor BCL7B functions in the Wnt signaling pathway. PLoS Genet. 2015; 11:e1004921. PMID: 25569233.

8. Dose M, Emmanuel AO, Chaumeil J, Zhang J, Sun T, Germar K, et al. β-Catenin induces T-cell transformation by promoting genomic instability. Proc Natl Acad Sci U S A. 2014; 111:391–396. PMID: 24371308.

9. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351:657–667. PMID: 15306667.

10. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature. 2006; 440:105–109. PMID: 16400328.